JP2011528797A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011528797A5 JP2011528797A5 JP2011519175A JP2011519175A JP2011528797A5 JP 2011528797 A5 JP2011528797 A5 JP 2011528797A5 JP 2011519175 A JP2011519175 A JP 2011519175A JP 2011519175 A JP2011519175 A JP 2011519175A JP 2011528797 A5 JP2011528797 A5 JP 2011528797A5
- Authority
- JP
- Japan
- Prior art keywords
- amount
- subject
- cardiac troponin
- angiogenic therapy
- reference amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004903 Troponin Human genes 0.000 claims 19
- 108090001027 Troponin Proteins 0.000 claims 19
- 230000000747 cardiac effect Effects 0.000 claims 18
- 238000011122 anti-angiogenic therapy Methods 0.000 claims 16
- 238000000034 method Methods 0.000 claims 15
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 10
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 10
- 239000005557 antagonist Substances 0.000 claims 10
- 108020001621 Natriuretic Peptide Proteins 0.000 claims 8
- 102000004571 Natriuretic peptide Human genes 0.000 claims 8
- 239000000692 natriuretic peptide Substances 0.000 claims 8
- 102400001263 NT-proBNP Human genes 0.000 claims 2
- 102000004987 Troponin T Human genes 0.000 claims 2
- 108090001108 Troponin T Proteins 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 230000007211 cardiovascular event Effects 0.000 claims 2
- 230000000977 initiatory effect Effects 0.000 claims 2
- 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000004165 myocardium Anatomy 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08161014.9 | 2008-07-23 | ||
| EP08161014 | 2008-07-23 | ||
| PCT/EP2009/059505 WO2010010153A1 (en) | 2008-07-23 | 2009-07-23 | Identification of subjects being susceptible to anti-angiogenesis therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011528797A JP2011528797A (ja) | 2011-11-24 |
| JP2011528797A5 true JP2011528797A5 (https=) | 2012-01-12 |
| JP5606438B2 JP5606438B2 (ja) | 2014-10-15 |
Family
ID=40162929
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011519175A Active JP5606438B2 (ja) | 2008-07-23 | 2009-07-23 | 抗血管新生療法を受容可能な被験体の同定 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9983213B2 (https=) |
| EP (1) | EP2321651B1 (https=) |
| JP (1) | JP5606438B2 (https=) |
| ES (1) | ES2644723T3 (https=) |
| WO (1) | WO2010010153A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE029661T2 (en) | 2009-10-16 | 2017-03-28 | Oncomed Pharm Inc | A therapeutic combination and use of DLL4 antagonist antibodies and antihypertensive agents |
| US10260097B2 (en) * | 2011-06-02 | 2019-04-16 | Almac Diagnostics Limited | Method of using a gene expression profile to determine cancer responsiveness to an anti-angiogenic agent |
| LT3485903T (lt) | 2011-09-23 | 2023-02-27 | Mereo Biopharma 5, Inc. | Vegf/ dll4 surišantys agentai ir jų panaudojimas |
| US9599620B2 (en) | 2012-10-31 | 2017-03-21 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a DLL4 antagonist |
| SG11201504023SA (en) | 2012-12-03 | 2015-06-29 | Almac Diagnostics Ltd | Molecular diagnostic test for cancer |
| GB201409479D0 (en) | 2014-05-28 | 2014-07-09 | Almac Diagnostics Ltd | Molecular diagnostic test for cancer |
| ES2808153T3 (es) | 2014-10-31 | 2021-02-25 | Mereo Biopharma 5 Inc | Terapia de combinación para tratamiento de enfermedad |
| US11339213B2 (en) | 2015-09-23 | 2022-05-24 | Mereo Biopharma 5, Inc. | Methods and compositions for treatment of cancer |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| US6582959B2 (en) | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
| GB9211686D0 (en) | 1992-06-03 | 1992-07-15 | Medisinsk Innovation A S | Chemical compounds |
| AU687727B2 (en) | 1992-10-28 | 1998-03-05 | Genentech Inc. | Vascular endothelial cell growth factor antagonists |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| KR100816621B1 (ko) | 1997-04-07 | 2008-03-24 | 제넨테크, 인크. | 항-ｖｅｇｆ 항체 |
| EP1165059A4 (en) * | 1999-03-15 | 2003-03-05 | Boston Life Sciences Inc | PHARMACEUTICAL COMPOSITIONS INCLUDE THE UNITS OF TROPONIN, FRAGMENTS THEREOF AND THEIR HOMOLOGOUS AND METHODS FOR THEIR USE TO INHIBIT ANGIOGENESIS |
| US6703020B1 (en) | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
| WO2001061048A2 (en) * | 2000-02-17 | 2001-08-23 | Millennium Pharmaceuticals, Inc. | Methods and compositions for the identification, assessment, prevention and therapy of human cancers |
| US7632647B2 (en) | 2001-04-13 | 2009-12-15 | Biosite Incorporated | Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes |
| EP1322957B1 (en) | 2001-05-04 | 2009-08-12 | Biosite Incorporated | Diagnostic markers of acute coronary syndromes and methods of use thereof |
| UA101945C2 (uk) * | 2003-05-30 | 2013-05-27 | Дженентек, Инк. | Лікування злоякісного новоутворення за допомогою бевацизумабу |
| WO2005044853A2 (en) | 2003-11-01 | 2005-05-19 | Genentech, Inc. | Anti-vegf antibodies |
| EP1759214B1 (en) * | 2004-06-15 | 2013-04-24 | F.Hoffmann-La Roche Ag | The use of cardiac hormones for diagnosing the risk of suffering from a cardiovascular complication as a consequence of cardiotoxic medication |
| US7939267B2 (en) * | 2004-11-04 | 2011-05-10 | Laboratory Corporation Of America Holdings | Detection of activation of endothelial cells as surrogate marker for angiogenesis |
| DK1849009T3 (da) * | 2005-01-24 | 2009-01-12 | Hoffann La Roche Ag F | Anvendelse af cardiachormoner til diagnose af cardiovaskulære risici som fölge af en administration af antiinflammatoriske lægemidler |
| CA2615636A1 (en) * | 2005-08-12 | 2007-02-22 | Regeneron Pharmaceuticals, Inc. | Treatment of diseases by subcutaneous administration of a vegf antagonist |
| JP5308328B2 (ja) | 2006-04-04 | 2013-10-09 | シングレックス，インコーポレイテッド | トロポニンの分析のための高感度のシステムおよび方法 |
| EP1887361A1 (en) * | 2006-08-07 | 2008-02-13 | Bio-Rad Pasteur | Method for the prediction of vascular events |
| EP1890154B1 (en) | 2006-08-16 | 2012-07-04 | F. Hoffmann-La Roche AG | Cardiac troponin as an indicator of advanced coronary artery disease |
| US20100111963A1 (en) | 2006-11-10 | 2010-05-06 | Genentech, Inc. | Method for treating age-related macular degeneration |
| EP2089719A2 (en) * | 2006-11-21 | 2009-08-19 | Roche Diagnostics GmbH | Means and methods for optimization of diagnostic and therapeutic approaches in chronic artery disease based on troponin t and nt-probnp |
| JP2011528798A (ja) | 2008-07-23 | 2011-11-24 | エフ．ホフマン−ラ ロシュ アーゲー | 抗血管形成療法のモニター |
-
2009
- 2009-07-23 EP EP09800069.8A patent/EP2321651B1/en active Active
- 2009-07-23 ES ES09800069.8T patent/ES2644723T3/es active Active
- 2009-07-23 WO PCT/EP2009/059505 patent/WO2010010153A1/en not_active Ceased
- 2009-07-23 JP JP2011519175A patent/JP5606438B2/ja active Active
-
2011
- 2011-01-20 US US13/010,183 patent/US9983213B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011528797A5 (https=) | ||
| JP2011506917A5 (https=) | ||
| WO2016094761A3 (en) | Test apparatus and methods for st2 cardiac biomarker | |
| JP2015519564A5 (https=) | ||
| JP2015502547A5 (https=) | ||
| JP2013533977A5 (https=) | ||
| JP2012073260A5 (https=) | ||
| WO2009063840A1 (ja) | エンドトキシンの濃度測定方法および濃度測定用キット | |
| WO2010002911A3 (en) | Methods and materials for monitoring myeloma using quantitative mass spetrometry | |
| JP2015520378A5 (https=) | ||
| JP2013545988A5 (https=) | ||
| JP2013060443A5 (https=) | ||
| BRPI1007867B8 (pt) | anticorpo recombinante ou fragmento de ligação ao antígeno do mesmo, composição farmacêutica e kit compreendendo o referido anticorpo, métodos de detecção de antígeno de troponina i em uma amostra de teste e métodos in vitro de diagnóstico de síndrome coronariana aguda ou infarto do miocárdio em um paciente | |
| JP2014521925A5 (https=) | ||
| WO2011061944A8 (ja) | 蛍光免疫測定方法 | |
| WO2013083781A3 (en) | Biomarkers and test panels useful in systemic inflammatory conditions | |
| JP2015529199A5 (https=) | ||
| WO2013092611A3 (en) | Method for the detection of free binding partner of a multispecific binder | |
| BR112012019475A8 (pt) | uso de um anticorpo monoclonal anti-cd44, anticorpo monoclonal anti-cd44, anticorpo anti-cd44 humanizado e kit para a detecção da presença de hnscc em uma amostra | |
| MX349661B (es) | Metodo para la deteccion de una molecula de union de un enlazador multiespecifico. | |
| JP2014533372A5 (https=) | ||
| RU2015104737A (ru) | Способ обнаружения мультиспецифического связывающего агента | |
| JP2010522699A5 (https=) | ||
| RU2012148711A (ru) | Способ и набор для диагностики злокачественной опухоли | |
| WO2012032345A3 (en) | Biomarker signatures and uses thereof |